Novo Nordisk’s Wegovy Shows Weight Loss-Independent Liver Benefits in MASH Trial Data

Novo Nordisk (NYSE:NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk ...

Novo Nordisk to offer select doses of Ozempic, Wegovy at a steep discount

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk slashes out-of-pocket prices for Wegovy and Ozempic for some customers

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Novo Nordisk: Will Wegovy And Pipeline Spark Rally?

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Novo Nordisk rolls out $349 Wegovy cash price ahead of plan

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Novo chops Wegovy prices, but doctors still see affordability challenges for patients

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Does Novo Nordisk's (CPSE:NOVO B) Alzheimer’s Setback Challenge Its Long-Term Diversification Ambitions?

On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of ...